Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers
V Prasad, V Kaestner, S Mailankody - JAMA oncology, 2018 - jamanetwork.com
On May 23, 2017, the US Food and Drug Administration (FDA) granted accelerated approval
to pembrolizumab (Keytruda, Merck & Co) for patients with unresectable or metastatic, …
to pembrolizumab (Keytruda, Merck & Co) for patients with unresectable or metastatic, …
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
V Prasad, V Kaestner - Seminars in oncology, 2017 - Elsevier
Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda,
Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved …
Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved …
A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals
…, A Haslam, T Crain, J Gill, C Livingston, V Kaestner… - Elife, 2019 - elifesciences.org
10.7554/eLife.45183.001 The ability to identify medical reversals and other low-value
medical practices is an essential prerequisite for efforts to reduce spending on such practices. …
medical practices is an essential prerequisite for efforts to reduce spending on such practices. …
Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes
MJ Hayes, V Kaestner, S Mailankody… - … Association Open Access …, 2018 - cmajopen.ca
Background: In a 2003 paper in BMJ, the authors made the tongue-in-cheek observation
that there are no randomized controlled trials (RCTs) of parachutes. This paper has been …
that there are no randomized controlled trials (RCTs) of parachutes. This paper has been …
Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug …
…, J Ruby, A Lammers, S Mailankody, V Kaestner… - bmj, 2018 - bmj.com
Objective To determine the differences between recommendations by the National Comprehensive
Cancer Network (NCNN) guidelines and Food and Drug Administration approvals of …
Cancer Network (NCNN) guidelines and Food and Drug Administration approvals of …
Conflicts of interest in Twitter
We have previously shown that 79· 5% of US-based haematologistoncologists on Twitter
have at least one financial conflict of interest (FCOI) 1 with the biopharmaceutical industry. …
have at least one financial conflict of interest (FCOI) 1 with the biopharmaceutical industry. …
The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study
V Kaestner, JB Edmiston, V Prasad - Canadian Medical Association …, 2018 - cmajopen.ca
Background: Despite the abundant research on financial conflict of interest regarding provider
behaviour and the interpretation and results of research, little is known about the relation …
behaviour and the interpretation and results of research, little is known about the relation …
Financial conflict of interest and academic influence among experts speaking on behalf of the pharmaceutical industry at the US food and drug administration's …
…, J Edmiston, V Kaestner… - Mayo Clinic …, 2017 - mayoclinicproceedings.org
Methods We reviewed transcripts, presentation slides, and supplemental documents for all
Oncology Drug Advisory Committee (ODAC) meetings concerning a specific drug product …
Oncology Drug Advisory Committee (ODAC) meetings concerning a specific drug product …
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies—Reply
V Prasad, V Kaestner, S Mailankody - JAMA oncology, 2018 - jamanetwork.com
1. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for
persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018; 4 (2): 196-…
persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018; 4 (2): 196-…
[PDF][PDF] Evaluating Language Competency After a Medical Spanish Immersion Program
V Kaestner, J Meany - drexel.edu
BACKGROUND Many medical students attend immersion programs to improve language
skills with the hopes of learning how to assess and treat patients in that language. It is …
skills with the hopes of learning how to assess and treat patients in that language. It is …